KHTRF News and Press, Knight Therapeutics Inc From 10/31/22

Summary RIGL hoped to expand the label of its drug Tavalisse (fostamatinib), but the failure of the drug in phase 3 appeared to scupper its chances. RIGL sought guidance to see if a reanalysis of the failed phase 3 study might be well received, but it doesn't appear it was. Th...

Knight Therapeutics, Inc. (KHTRF) Q2 2022 Earnings Conference Call August 11, 2022, 8:30 am ET Company Participants Samira Sakhia - President & CEO Amal Khouri - CBO Arvind Utchanah - CFO Jeff Martens - Global VP, Commercial Conference Call Particip...

Knight Therapeutics press release ( OTCPK:KHTRF ): Q2 GAAP EPS of C$0.02. Revenue of C$75.82M (+15.2% Y/Y). For further details see: Knight Therapeutics GAAP EPS of C$0.02, revenue of C$75.82M

Knight Therapeutics (OTC:KHTRF) has entered into exclusive license and supply pacts with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase inhibitor, in Latin America. Per the terms, Rigel will receive an upfront cash paym...

Knight Therapeutics Inc. (KHTRF) Q1 2022 Earnings Conference Call May 12, 2022, 08:30 AM ET Company Participants Samira Sakhia - President and CEO Amal Khouri - Chief Business Officer Arvind Utchanah - CFO Jeff Martens - Global VP, Commercial Conference Call Participants Doug Miehm - RBC Capi...

Knight Therapeutics press release (OTC:KHTRF): Q1 GAAP EPS of -C$0.16. Revenue of C$63.81M (+38.5% Y/Y). For further details see: Knight Therapeutics GAAP EPS of -C$0.16, revenue of C$63.81M

Knight Therapeutics Inc. (KHTRF) Q4 2021 Earnings Conference Call March 24 2022, 08:30 AM ET Company Participants Samira Sakhia – President and CEO Jeff Martens - Global VP, Commercial Arvind Utchanah - CFO Amal Khouri - Chief Business Officer Conference Call Participants Justin Keywoo...

Knight Therapeutics Inc. (KHTRF) Q3 2021 Earnings Conference Call November 11, 2021 08:30 ET Company Participants Samira Sakhia - President and Chief Executive Officer Amal Khouri - Chief Business Officer Arvind Utchanah - Chief Financial Officer Jeff Martens - Global Vice President, Commerci...

Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), and Knight Therapeutics (OTC:KHTRF) have entered into an agreement for the exclusive rights to distribute tafasitamab (Monjuvi) and pemigatinib (Pemazyre) in Latin America. Under the terms...

Knight Therapeutics Inc. (KHTRF) Q2 2021 Earnings Conference Call August 13, 2021, 08:30 AM ET Company Participants Jonathan Ross Goodman - Chief Executive Officer Samira Sakhia - President, Chief Operating Officer and Director Amal Khouri - Chief Business Officer Arvind Utchanah - Chief Fina...